This milestone shows the devotion of our QA team to ensuring HEMEX’s high standards and commitment to quality. Achieving this certification was one of the milestones we wished to accomplish in 2022.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Only six months after closing its seed round of CHF 2.1 million, the successful healthtech start-up closes its pre-series A financing round of CHF 3.3 million. With this new capital, Sedimentum intends to conquer the Swiss B2C market with its intelligent SAFE-living solution.
Eating healthier, regular exercise, or reading more books – many people use the New Year to tackle new projects or follow through on old plans. What’s on your list of New Year’s resolutions for 2022?
Apply by January 16 to the Venture Leaders Technology program, where you’ll meet industry leaders and top technology investors in Silicon Valley
Market tracking is not only exciting but has recently become a requirement under the Medical Device regulations (MDR) of the EU. Join us in learning what steps are necessary to complete the post-market clinical follow-up!
We’re delighted to announce that our portfolio startup Resistell AG has completed the pilot phase of its clinical Performance Evaluation
Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.
Unique cultures, different opportunities, and many smiles: Meet the team working towards a common goal!
We’re delighted to announce a new collaboration between HEMEX and The Bioinformatics CRO which will provide an even more complete CRO service for our start-ups! Find out how this collaboration can support you throughout your Clinical Development phase.
Complicated words and sentences may be misunderstood and are very often unfamiliar to the patients. This led us to discuss how we could find the optimal solution for all parties involved in a clinical study: the patient, physician, and sponsor/CRO.